IP Library › Granted Patent US 9,657,009
Granted Patent B2
US 9,657,009 · App. 14/441,705 · Granted May 23, 2017

Heteroaryl substituted pyridyl compounds useful as kinase modulators

Inventors: Rajeev S. Bhide (Princeton Junction, NJ); John V. Duncia (Newtown, PA); John Hynes (Washington Crossing, PA); Satheesh K. Nair (Bangalore, IN); William J. Pitts (Newtown, PA); Sreekantha R. Kumar (Bangalore, IN); Daniel S. Gardner (Furlong, PA); Natesan Murugesan (Princeton Junction, NJ); Venkatram Reddy Paidi (Bangalore, IN); Joseph B. Santella (Springfield, PA); Ramesh Sistla (Bangalore, IN); Hong Wu (New Hope, PA)
Assignee: Bristol-Myers Squibb Company
C07D417/14C07D213/74C07D401/12C07D401/14C07D405/12C07D405/14C07D407/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,657,009
App. No.
14/441,705
Granted
May 23, 2017
Kind
B2
Abstract

Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R 2 is a monocyclic heteroaryl group, and R 1 , R 3 , R 4 , R 5 and R 6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

Claims (138)

1. A compound of Formula (II)

or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein:

R 1 is:

(a) C 2-3 hydroxyalkyl substituted with zero to 4 R 1a wherein R 1a is independently selected from F, Cl, —OH, —CHF 2 , —CN, —CF 3 , —OCH 3 , and cyclopropyl;

(b) C 1-3 alkyl substituted with —O(C 1-3 alkyl) and zero to 4 R 1a wherein R 1a is independently selected from F, Cl, —OH, —CHF 2 , —CN, —CF 3 , and cyclopropyl;

(c) C 4-8 alkyl substituted with zero to 7 R 1a wherein R 1a is independently selected from F, Cl, —OH, —CHF 2 , —CF 3 , —CN—OCH 3 , cyclopropyl, and —OP(O)(OH) 2 ;

(d) —(CH 2 ) 2-4 NHC(O)(C 1-6 alkyl), —(CH 2 ) 2 CH(CH 3 )NHC(O)(C 1-6 alkyl), —(CH 2 ) 2 CH(CH 3 )NHC(O)(CH 2 ) 0-1 NH(C 1-6 alkyl), or —(CH 2 ) 2 CH(CH 3 )NHC(O)(CH 2 ) 0-1 N(C 1-4 alkyl) 2 ;

(e) cyclohexyl substituted with zero to 2 substituents independently selected from —OH, —OCH 3 , C 1-6 alkyl, C 1-6 hydroxyalkyl, —C(O)NH 2 , —C(O)NH(C 1-3 alkyl), —C(O)NH(C 1-6 hydroxyalkyl), —C(O)NH(C 3-6 cycloalkyl), —C(O)NH(C 3-6 fluoro cycloalkyl), —NHC(O)(C 1-3 alkyl), —NHC(O)O(C 1-3 alkyl), —NHS(O) 2 CH 3 , —S(O) 2 NH 2 , —S(O) 2 (C 1-3 alkyl), —S(C 1-3 alkyl), and C 1-3 alkyl substituted with —OH and cyclopropyl; or

(f) —(CH 2 ) 2 (phenyl) wherein said phenyl is substituted with —C(O)NH 2 , —C(O)NH(C 1-3 alkyl), or —S(O) 2 NH 2 ;

R 2 is pyridinyl substituted with zero to 2 substituents independently selected from F, Cl, —OH, —CN, C 1-3 alkyl, —CH 2 C(O)OCH 3 , —O(C 1-3 alkyl), —NH 2 , —NH(C 1-3 alkyl), —NH(cyclopropyl), —C(O)NH 2 , —NHC(O)(C 1-3 alkyl), and ═O; and

R 3 is:

(a) C 1-6 alkyl substituted with zero to 4 substituents independently selected from F, —OH, —CH 3 , —CF 3 , and C 3-6 cycloalkyl;

(b) C 3-6 cycloalkyl substituted with zero to 2 substituents independently selected from F, —OH, C 1-3 hydroxyalkyl, —CH 3 , —CF 2 H, —NH 2 , and —C(O)OCH 2 CH 3 ;

(c) phenyl substituted with zero to 2 substituents independently selected from —OH, —CN, —O(C 1-3 alkyl), C 1-3 hydroxyalkyl, —C(O)NH 2 , —S(O) 2 NH 2 , and —NHS(O) 2 (C 1-3 alkyl); or

(d)

2. The compound according to claim 1 or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein:

R 1 is:

(a) C 1-3 alkyl substituted with —O(C 1-3 alkyl) and zero to 4 R 1a wherein R 1a is independently selected from F, —OH, and —CF 3 ;

(b) C 4-8 alkyl substituted with zero to 5 R 1a wherein R 1a is independently selected from F, Cl, —OH, —CHF 2 , —CF 3 , —CN—OCH 3 , cyclopropyl, and —OP(O)(OH) 2 ;

(c) —(CH 2 ) 2-4 NHC(O)(C 1-3 alkyl), —(CH 2 ) 2 CH(CH 3 )NHC(O)(C 1-3 alkyl), —(CH 2 ) 2 CH(CH 3 )NHC(O)NH(C 1-3 alkyl), or —(CH 2 ) 2 CH(CH 3 )NHC(O)N(C 1-3 alkyl) 2 ;

(d) cyclohexyl substituted with zero to 2 substituents independently selected from —OH, —OCH 3 , C 1-3 alkyl, C 1-3 hydroxyalkyl, —C(O)NH 2 , —C(O)NH(C 1-3 alkyl), —C(O)NH(C 3-5 cycloalkyl), —C(O)NH(fluoro cyclopropyl), —NHC(O)(C 1-3 alkyl), —NHC(O)O(C 1-3 alkyl), —S(O) 2 NH 2 , —S(O) 2 (C 1-2 alkyl), —S(C 1-2 alkyl), and C 1-3 alkyl substituted with —OH and cyclopropyl; or

(e) —(CH 2 ) 2 (phenyl) wherein said phenyl is substituted with —C(O)NH 2 , —C(O)NH(CH 3 ), or —S(O) 2 NH 2 ;

and

R 3 is:

(a) C 1-5 alkyl substituted with zero to 3 substituents independently selected from F, —OH, —CH 3 , —CF 3 , and cyclopropyl;

(b) C 3-6 cycloalkyl substituted with zero to 2 substituents independently selected from F, —OH, C 1-3 hydroxyalkyl, —CH 3 , —CF 2 H, —NH 2 , and —C(O)OCH 2 CH 3 ;

(c) phenyl substituted with zero to 2 substituents independently selected from —OH, —CN, —OCH 3 , C 1-2 hydroxyalkyl, —C(O)NH 2 , —S(O) 2 NH 2 , and —NHS(O) 2 CH 3 ; or

(d)

3. The compound according to claim 1 or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein:

R 1 is: —CH 2 CHFC(CH 3 ) 2 OH, —CH 2 CHFC(CH 3 ) 2 OCH 3 , —CH 2 CHFC(CH 2 CH 3 ) 2 OH, —CH 2 CHFCH 2 OCH 3 , —(CH 2 ) 3 OCH 3 , —(CH 2 ) 3 OC(CH 3 ) 3 , —CH 2 CF 2 C(CH 3 ) 2 OH, —(CH 2 ) 2 CH(CH 3 )NHC(O)CH 3 , —(CH 2 ) 2 CH(CH 3 )NHC(O)NHCH(CH 3 ) 2 , —CH 2 CHFC(CH 3 ) 2 OP(O)(OH) 2 ,

R 2 is

and

R 3 is C 2-5 alkyl, —CH 2 CF 3 , —CH 2 C(CH 3 ) 2 F, —CH(CH 3 )CHFCH 3 , —CH(CH 3 )CH 2 F, —CH(CH 3 )CH 2 CH 2 F, —CH(CH 3 )CH 2 OH, —CH 2 C(CH 3 ) 2 OH, —CH 2 CF 2 C(CH 3 ) 2 OH, —CH(CH 3 )(cyclopropyl), C 3-4 cycloalkyl,

4. The compound according to claim 1 or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R 1 is:

(a) C 1-3 alkyl substituted with —O(C 1-3 alkyl) and zero to 4 R 1a wherein R 1a is independently selected from F, —OH, and —CF 3 ;

(b) C 4-8 alkyl substituted with zero to 5 R 1a wherein R 1a is independently selected from F, Cl, —OH, —CHF 2 , —CF 3 , —CN—OCH 3 , cyclopropyl, and —OP(O)(OH) 2 ; or

(c) —(CH 2 ) 2-4 NHC(O)(C 1-3 alkyl), —(CH 2 ) 2 CH(CH 3 )NHC(O)(C 1-3 alkyl), —(CH 2 ) 2 CH(CH 3 )NHC(O)NH(C 1-3 alkyl), or —(CH 2 ) 2 CH(CH 3 )NHC(O)N(C 1-3 alkyl) 2 .

5. The compound according to claim 1 or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R 1 is cyclohexyl substituted with zero to 2 substituents independently selected from —OH, —OCH 3 , C 1-3 alkyl, —OCH 3 , C 1-3 hydroxyalkyl, —C(O)NH 2 , —C(O)NH(C 1-3 alkyl), —C(O)NH(C 3-5 cycloalkyl), —C(O)NH(fluoro cyclopropyl), —NHC(O)(C 1-3 alkyl), —NHC(O)O(C 1-3 alkyl), —S(O) 2 NH 2 , —S(O) 2 (C 1-2 alkyl), —S(C 1-2 alkyl), and C 1-3 alkyl substituted with —OH and cyclopropyl.

6. The compound according to claim 1 or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R 3 is C 2-5 alkyl, —CH 2 CF 3 , —CH 2 C(CH 3 ) 2 F, —CH(CH 3 )CHFCH 3 , —CH(CH 3 )CH 2 F, —CH(CH 3 )CH 2 CH 2 F, —CH(CH 3 )CH 2 OH, —CH 2 C(CH 3 ) 2 OH, —CH 2 CF 2 C(CH 3 ) 2 OH, or —CH(CH 3 )(cyclopropyl).

7. The compound according to claim 1 or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R 3 is C 3-4 cycloalkyl,

8. The compound according to claim 1 or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R 3 is

9. The compound according to claim 1 or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein R 2 is

10. A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier or diluent.

11. A compound according to claim 1 or a pharmaceutically-acceptable salt thereof, selected from:

6-((5-Cyano-2-pyridinyl)amino)-4-(((1S,2S)-2,3-dihydroxy-1-phenylpropyl)amino)-N-methylnicotinamide (1);

6-((5-Cyano-2-pyridinyl)amino)-N-((2R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (2);

(R)-6-((5-cyanopyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(2,2,2-trifluoroethyl)amino)nicotinamide (3);

(R)-6-((5-cyanopyridin-2-yl)amino)-4-(ethylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl) nicotinamide (4);

6-((5-cyanopyridin-2-yl)amino)-4-(isopropylamino)-N-((1r,4r)-4-(methylcarbamoyl)cyclohexyl) nicotinamide (5);

6-((5-cyanopyridin-2-yl)amino)-N-((1r,4r)-4-(cyclopropylcarbamoyl)cyclohexyl)-4-(isopropylamino)nicotinamide (6);

6-((5-cyanopyridin-2-yl)amino)-N-((1S,4r)-4-(((1S,2R)-2-fluorocyclopropyl)carbamoyl) cyclohexyl)-4-(isopropylamino)nicotinamide (7);

N-((1r,4r)-4-acetamidocyclohexyl)-6-((5-cyanopyridin-2-yl)amino)-4-(isopropylamino) nicotinamide (9);

N-((1r,4r)-4-acetamidocyclohexyl)-6-((5-cyanopyridin-2-yl)amino)-4-(cyclobutylamino) nicotinamide (10);

6-((3-chloro-5-cyano-2-pyridinyl)amino)-N-((2R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (12);

6-((3-chloro-5-cyano-2-pyridinyl)amino)-4-(cyclopropylamino)-N-((2R)-2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (14);

N-((1r,4r)-4-acetamidocyclohexyl)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-(isopropylamino) nicotinamide (15);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-(isopropylamino)-N-((1R,4R)-4-(methylcarbamoyl) cyclohexyl)nicotinamide (16);

6-((5-cyano-3-fluoro-2-pyridinyl)amino)-N-((2R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (17);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(isopropylamino)-N-((1R,4R)-4-(methylcarbamoyl) cyclohexyl)nicotinamide (18);

N-(trans-4-acetamidocyclohexyl)-6-((5-cyano-3-fluoro-2-pyridinyl)amino)-4-(isopropylamino) nicotinamide (19);

(R)—N-(3-acetamidobutyl)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-(isopropylamino) nicotinamide (28);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(isopropylamino)-N-(3-(3-isopropylureido) butyl)nicotinamide (29);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-((1r,4r)-4-(ethylcarbamoyl)cyclohexyl)-4-(isopropylamino)nicotinamide (30);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(isopropylamino)-N-((1r,4r)-4-(methylthio) cyclohexyl)nicotinamide (32);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(isopropylamino)-N-((1r,4r)-4-(methyl sulfonyl) cyclohexyl)nicotinamide (33);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-methoxypropyl)-4-(isopropylamino) nicotinamide (35);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-methoxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (36);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-(methoxy-d 3 )-3-methylbutyl)-4-(isopropylamino)nicotinamide (37);

6-((5-carbamoyl-3-chloropyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(3-fluorocyclopentyl)amino)nicotinamide (38);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((S)-1-fluoropropan-2-yl)amino)nicotinamide (39);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-(cyclopropylamino)-N-(2,2-difluoro-3-hydroxy-3-methylbutyl)nicotinamide (43);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(4-(1-cyclopropyl-1-hydroxyethyl)cyclohexyl)-4-(isopropylamino)nicotinamide (44);

(R)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-((2-fluoro-2-methylpropyl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (46);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(cyclopropylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (47);

(R)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((2-hydroxy-2-methylpropyl)amino)nicotinamide (48);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((S)-1-hydroxypropan-2-yl)amino)nicotinamide (50);

(R)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-(ethylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (51);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-fluorocyclopentyl)amino)nicotinamide (57);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(cyclopropylamino)-N-((1r,4r)-4-(methylcarbamoyl) cyclohexyl)nicotinamide (59);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-(cyclopropylamino)-N-((1r,4r)-4-(methylcarbamoyl) cyclohexyl)nicotinamide (60);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-fluorocyclopentyl)amino)nicotinamide (62);

(R)-6-((5-cyano-6-methylpyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (63);

(R)—N-(3-acetamidobutyl)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(isopropyl amino) nicotinamide (64);

(R)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(2,2,2-trifluoroethyl)amino)nicotinamide (65);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(ethylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (66);

N-((1r,4r)-4-acetamidocyclohexyl)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamide (67);

(R)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-(isopropylamino)-N-(3-(3-methylureido)butyl) nicotinamide (68);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((2-fluorocyclopentyl)amino)nicotinamide (70, 71, 73, and 74);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((2-hydroxycyclopentyl)amino)nicotinamide (76 and 78);

(R)-6-((3,5-difluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (80);

(R)-6-((5-chloropyridin-2-yl)amino)-4-(cyclopropylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (81);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-fluorocyclopentyl)amino)nicotinamide (82);

N-((1r,4r)-4-acetamidocyclohexyl)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(cyclopropylamino)nicotinamide (83);

(R)-6-((3,5-dichloropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (84);

(R)-6-((5-cyano-3-methylpyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (85);

(R)-4-(cyclopropylamino)-6-((3,5-difluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (89);

(R)-4-(bicyclo[1.1.1]pentan-1-ylamino)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (90);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((S)-1-hydroxypropan-2-yl)amino)nicotinamide (91);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N-((1r,4r)-4-hydroxycyclohexyl)-4-(isopropylamino)nicotinamide (92);

6-((3,5-difluoropyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((R)-1-hydroxypropan-2-yl)amino)nicotinamide (100);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N-(4-(2-hydroxypropan-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (102);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-((2-fluoro-2-methylpropyl)amino)-N-(4-(2-hydroxypropan-2-yl)cyclohexyl)nicotinamide (103);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((2-hydroxycyclohexyl)amino)nicotinamide (104);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-fluorocyclopentyl)amino)nicotinamide (114 and 115);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(isopropylamino)-N-((1r,4r)-4-(isopropylcarbamoyl)cyclohexyl)nicotinamide (116);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-((1r,4r)-4-(cyclopropylcarbamoyl)cyclohexyl)-4-(isopropylamino)nicotinamide (118);

4-(((1s,3S)-adamantan-1-yl)amino)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (119);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-(isopropylamino)-N-(3-methoxypropyl)nicotinamide (120);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(isopropylamino)-N-(4-sulfamoylphenethyl)nicotinamide (121);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-(hydroxymethyl)phenyl)amino)nicotinamide (122);

(R)-6-((5-chloro-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isopropylamino)nicotinamide (123);

(R)-6-((5-chloro-3-fluoropyridin-2-yl)amino)-4-(cyclopropylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (124);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-hydroxyphenyl)amino)nicotinamide (125);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-((2,2-difluoro-3-hydroxy-3-methylbutyl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (126);

N-(3-(tert-butoxy)propyl)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(isopropylamino) nicotinamide (127);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-sulfamoylphenyl)amino)nicotinamide (128);

(R)—N-(2-fluoro-3-hydroxy-3-methylbutyl)-6-((3-fluoro-5-methylpyridin-2-yl)amino)-4-(isopropylamino)nicotinamide (129);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-methoxyphenyl)amino)nicotinamide (130);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((4-hydroxybicyclo[2.2.1]heptan-1-yl)amino)nicotinamide (133);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-(methylsulfonamido)phenyl)amino)nicotinamide (134);

(R)-4-((3-carbamoylphenyl)amino)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (135);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-((1r,4r)-4-(2-hydroxypropan-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (137);

(R)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(propylamino)nicotinamide (138 and 140);

(R)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(propylamino)nicotinamide (139 and 141);

(R)-4-((4-carbamoylphenyl)amino)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (142);

(R)-4-((3-carbamoylphenyl)amino)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (143);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(4-(1-cyclopropyl-1-hydroxyethyl)cyclohexyl)-4-(isopropylamino)nicotinamide (144 and 145);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((1r,4R)-4-hydroxy-4-methylcyclohexyl)amino)nicotinamide (150);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-(cyclopropylamino)-N-((1r,4r)-4-(methylsulfonyl) cyclohexyl)nicotinamide (151);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((1s,4S)-4-hydroxy-4-methylcyclohexyl)amino)nicotinamide (152);

(R)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)-4-(isobutylamino)nicotinamide (155 and 156);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-((3-fluorocyclopentyl)amino)nicotinamide (157 and 158);

6-((3-chloro-5-cyanopyridin-2-yl)amino)-N—((R)-2-fluoro-3-hydroxy-3-methylbutyl)-4-(((2R)-3-fluorobutan-2-yl)amino)nicotinamide (159 and 160);

4-((3-carbamoylphenyl)amino)-6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-((1r,4r)-4-(methylsulfonyl)cyclohexyl)nicotinamide (161);

(R)-6-((3-chloro-5-cyanopyridin-2-yl)amino)-4-((3-cyanophenyl)amino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide (162);

methyl ((1r,4r)-4-(6-((5-cyano-3-fluoropyridin-2-yl)amino)-4-(isopropylamino)nicotinamido) cyclohexyl)carbamate (165);

6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(4-hydroxy-4-(1-methyl-1H-pyrazol-5-yl) cyclohexyl)-4-(isopropyl amino)nicotinamide (166); and

6-((5-cyano-3-fluoropyridin-2-yl)amino)-N-(4-hydroxy-4-(thiazol-2-yl)cyclohexyl)-4-(isopropylamino)nicotinamide (167).

Continuity (3)
Provisional Application 61774824 · Mar 8, 2013
Provisional Application 61723848 · Nov 8, 2012
Related Publication 20150284382A1 · Oct 8, 2015